Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Mosby-Elsevier
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Pleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fa-tal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant im-provements in diagnoses and treatments of many malignancies; however, there are still therapeutic chal-lenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncolo-gists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
Açıklama
Anahtar Kelimeler
Biomarker, Cancer, Chemotherapy, Immune Checkpoint Inhibitor, Immunotherapy, Pleural Mesothelioma
Kaynak
Current Problems In Cancer
WoS Q Değeri
N/A
Scopus Q Değeri
Q3
Cilt
47
Sayı
6
